Namuhla, ukukhuluphala sekuwumqedazwe womhlaba wonke, futhi izinga lokukhuluphala liye landa kakhulu emazweni omhlaba.Ngokwe-World Health Organization, kulinganiselwa ukuthi amaphesenti angu-13 abantu abadala emhlabeni akhuluphele ngokweqile.Okubaluleke nakakhulu, ukukhuluphala ngokweqile kungase kubangele i-metabolic syndrome, ehambisana nezinkinga ezihlukahlukene ezifana nohlobo 2 lwesifo sikashukela, umfutho wegazi ophakeme, i-nonalcoholic steatohepatitis (NASH), isifo senhliziyo, nomdlavuza.
NgoJuni 2021, i-FDA igunyaze i-Semaglutide, umuthi wokwehlisa isisindo owakhiwe nguNovo Nordisk, njengo-Wegovy.Ngenxa yemiphumela yayo emihle kakhulu yokulahlekelwa isisindo, iphrofayili enhle yokuphepha kanye nokucindezela okuvela kosaziwayo abafana no-Musk, i-Semaglutide isithandwa kakhulu emhlabeni wonke kangangokuthi kunzima ngisho nokuyithola.Ngokombiko wezezimali we-Novo Nordisk ka-2022, i-Semaglutide ikhiqize ukuthengiswa okufika ku-$12 billion ngo-2022.
Muva nje, ucwaningo olushicilelwe ku-Journal lubonise ukuthi i-Semaglutide nayo inenzuzo engalindelekile: ukubuyisela umsebenzi weseli obulalayo wemvelo (NK) emzimbeni, kuhlanganise nekhono lokubulala amangqamuzana omdlavuza, okungaxhomeki emiphumeleni yokulahlekelwa isisindo somuthi.Lolu cwaningo lubuye lube yizindaba ezinhle kakhulu ezigulini ezikhuluphele ezisebenzisa i-Semaglutide, eziphakamisa ukuthi izidakamizwa zinezinzuzo ezibalulekile ezingaba khona zokunciphisa ingozi yomdlavuza ngaphezu kokulahlekelwa isisindo.Isizukulwane esisha sezidakamizwa, esimelelwe yi-Semaglutide, siguqula ukwelashwa kokukhuluphala futhi simangaze abacwaningi ngemiphumela yayo enamandla.
Ngakho, ubani ongathola ukuncipha okuhle kwesisindo kuwo?
Ngokokuqala ngqa, leli qembu lahlukanisa abantu abakhuluphele ngamaqembu amane: labo abadinga ukudla okwengeziwe ukuze bazizwe besuthi (ukulamba kobuchopho), labo abadla isisindo esivamile kodwa kamuva bazizwe belambile (ukulamba kwamathumbu), labo abadla ukuze babhekane nenkinga. imizwelo (ukulamba kwemizwelo), nalabo abanometabolism ohamba kancane (ama-metabolists ahamba kancane).Ithimba lithole ukuthi iziguli ezikhuluphele ezilambele amathumbu zisabela kangcono kule mithi emisha yokwehlisa isisindo ngezizathu ezingaziwa, kodwa abacwaningi bacabanga ukuthi kungenzeka ukuthi kungenxa yokuthi amazinga e-GLP-1 ayengekho phezulu, yingakho bekhuluphala futhi, ngenxa yalokho, nesisindo esingcono. ukulahlekelwa ngama-GLP-1 receptor agonists.
Ukukhuluphala manje sekubhekwa njengesifo esingelapheki, ngakho le mithi inconywa ukwelashwa isikhathi eside.Kodwa isikhathi esingakanani leso?Akucaci, futhi lesi yisiqondiso okufanele sihlolwe ngokulandelayo.
Ngaphezu kwalokho, le mithi emisha yokunciphisa isisindo yayisebenza kangangokuthi abanye abacwaningi baqala ukuxoxa ngokuthi singakanani isisindo esilahlekile.Ukuncipha kwesisindo akugcini nje ngokunciphisa amafutha kodwa kuholela ekuwohlokeni kwemisipha, futhi ukuwohloka kwemisipha kwandisa ingozi yesifo senhliziyo nemithambo yegazi, ukukhumuzeka kwamathambo, nezinye izimo, okuwukukhathazeka ngokukhethekile kwasebekhulile nalabo abanesifo senhliziyo nemithambo yegazi.Laba bantu bathinteka kulokho okubizwa ngokuthi yi-obesity fallacy - ukuthi ukwehla kwesisindo kuhlotshaniswa nokufa okuphezulu.
Ngakho-ke, amaqembu amaningana aseqalile ukuhlola imiphumela ye-dose ephansi yokusebenzisa le mithi yenoveli yokunciphisa isisindo ukubhekana nezinkinga ezihlobene nokukhuluphala ngokweqile, njenge-apnea, isifo sesibindi esinamafutha, kanye nesifo sikashukela sohlobo lwe-2, okungadingi ukulahlekelwa isisindo.
Isikhathi sokuthumela: Oct-23-2023